Prion diseases: fatal familial insomnia
DOI:
https://doi.org/10.12775/JEHS.2021.11.09.004Keywords
prion diseases, fatal familial insomnia, neurodegeneration, FFI treatment, prionAbstract
Introduction. Fatal familial insomnia (FFI) is one of the transmissible spongiform encephathalopathies characterized by neuronal loss, sleep impairment, subsequent non-specific disturbances of autonomic nervous system (e.g. tachycardia) and endocrine dysfunctions. It is fatal autosomal dominant prion disease, which is extremaly rare- FFI affects only about one person per milion annually. The aim of this study is to review the literature and systematize knowledge about fatal familial insomnia.
Brief description of the state of knowledge. The causative agent of this disease is a misfolded version of the physiological prion protein called PrP(Sc) in the brain. Major vulnerable regions in FFI are mediodorsal and anterior ventral nuclei of the thalamus. Average survival time after the onset of symptoms is 18 months. Hence molecular mechanisms involved in pathogenesis are poorly understood, the disease is incureable yet. However, there are a number of therapeutic options currently under investigation, e.g. immunotherapy or doxycycline usage.
Conclusions. Subsequent researches are essential to improve understending of fatal familial insomnia. The prime issue is to develop functioning therapeutic or preventive treatment. While some of presented terapeutic approches appers promising, all of them require profoud research.
References
Chen C, Dong XP. Epidemiological characteristics of human prion diseases. Infect Dis Poverty. 2016 Jun 2;5(1):47. doi: 10.1186/s40249-016-0143-8. PMID: 27251305; PMCID: PMC4890484.
Rossi M, Baiardi S, Parchi P. Understanding Prion Strains: Evidence from Studies of the Disease Forms Affecting Humans. Viruses. 2019 Mar 29;11(4):309. doi: 10.3390/v11040309. PMID: 30934971; PMCID: PMC6520670.
Llorens F, Zarranz JJ, Fischer A, Zerr I, Ferrer I. Fatal Familial Insomnia: Clinical Aspects and Molecular Alterations. Curr Neurol Neurosci Rep. 2017 Apr;17(4):30. doi: 10.1007/s11910-017-0743-0. PMID: 28324299.
Khan Z, Bollu PC, Fatal Familial Insomnia, StatPearls Publishing, Treasure Island (FL), 01 Mar 2018, PMID: 29489284
Cracco L, Appleby BS, Gambetti P. Fatal familial insomnia and sporadic fatal insomnia. Handb Clin Neurol. 2018;153:271-299. doi: 10.1016/B978-0-444-63945-5.00015-5. PMID: 29887141.
Rodríguez-Martínez AB, Alfonso-Sánchez MA, Peña JA, Sánchez-Valle R, Zerr I, Capellari S, Calero M, Zarranz JJ, de Pancorbo MM. Molecular evidence of founder effects of fatal familial insomnia through SNP haplotypes around the D178N mutation. Neurogenetics. 2008 May;9(2):109-18. doi: 10.1007/s10048-008-0120-x. Epub 2008 Mar 18. PMID: 18347820.
Dagvadorj A, Petersen RB, Lee HS, Cervenakova L, Shatunov A, Budka H, Brown P, Gambetti P, Goldfarb LG. Spontaneous mutations in the prion protein gene causing transmissible spongiform encephalopathy. Ann Neurol. 2002 Sep;52(3):355-9. doi: 10.1002/ana.10267. PMID: 12205650.
Lee HS, Goldfarb LG. Global distribution of fatal familial insomnia: founder or recurrent mutations. Neurogenetics. 2008 Oct;9(4):301-2; author reply 303-4. doi: 10.1007/s10048-008-0135-3. Epub 2008 Jun 21. PMID: 18568368; PMCID: PMC2583437.
Dimitri D, Jehel L, Dürr A, Lévy-Soussan M, Andreux V, Laplanche JL, Fossati P, Cohen D. Fatal familial insomnia presenting as psychosis in an 18-year-old man. Neurology. 2006 Jul 25;67(2):363-4. doi: 10.1212/01.wnl.0000225181.98341.74. PMID: 16864846.
Geschwind MD. Prion Diseases. Continuum (Minneap Minn). 2015 Dec;21(6 Neuroinfectious Disease):1612-38. doi: 10.1212/CON.0000000000000251. PMID: 26633779; PMCID: PMC4879966.
Zarranz JJ, Digon A, et al., Phenotypic variability in familial prion diseases due to the D178N mutation. J.Neurol.Neurosurg.Psychiatry. 2005;76:1491–6.
Schenkein J, Montagna P. Self management of fatal familial insomnia. Part 1: what is FFI? MedGenMed. 2006 Sep 14;8(3):65.
Zerr I, Schmitz M. Genetic Prion Disease. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® University of Washington, Seattle; Seattle (WA): Mar 27, 2003.
Cortelli P, Perani D, Parchi P, et al. Cerebral metabolism in fatal familial insomnia: relation to duration, neuropathology, and distribution of protease-resistant prion protein. Neurology 1997; 49: 126– 133.
Cortelli P, Perani D, Montagna P, et al. Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain 2006; 129: 668– 675.
Vincenzo Mastrangelo MD, Elena Merli MD, Janet C. Rucker MD, Eric R. Eggenberger DO, David S. Zee MD, Pietro Cortelli MD, PhD, Neuro-Ophthalmological Findings in Early Fatal Familial Insomnia, 02 January 2021, https://doi.org/10.1002/ana.26008
Capellari S, Strammiello R, Saverioni D, Kretzschmar H, Parchi P. Genetic Creutzfeldt-Jakob disease and fatal familial insomnia: insights into phenotypic variability and disease pathogenesis. Acta Neuropathol. 2011;121:21–37.
Schmitz M, Dittmar K, Llorens F, Gelpi E, Ferrer I, SchulzSchaeffer WJ, Zerr I. Hereditary human prion diseases: an update. Mol.Neurobiol. 2016 Jun;20
Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: classification and characterisation. Br Med Bull. 2003;66:213-39. doi: 10.1093/bmb/66.1.213. PMID: 14522861.
Montagna P, Gambetti P, Cortelli P, Lugaresi E. Familial and sporadic fatal insomnia. Lancet Neurol. 2003 Mar;2(3):167-76. doi: 10.1016/s1474-4422(03)00323-5. PMID: 12849238.
Sforza E, Montagna P, Tinuper P, Cortelli P, Avoni P, Ferrillo F, Petersen R, Gambetti P, Lugaresi E. Sleep-wake cycle abnormalities in fatal familial insomnia. Evidence of the role of the thalamus in sleep regulation. Electroencephalogr Clin Neurophysiol. 1995 Jun;94(6):398-405. doi: 10.1016/0013-4694(94)00318-f. PMID: 7607093.
Ortega-Cubero S, Luquín MR, Domínguez I, Arbizu J, Pagola I, Carmona-Abellán MM, Riverol M. Structural and functional neuroimaging in human prion diseases. Neurologia. 2013 Jun;28(5):299-308. English, Spanish. doi: 10.1016/j.nrl.2011.03.012. Epub 2011 May 31. PMID: 21621879.
Klöppel S, Pirker W, Brücke T, Kovács GG, Almer G. Beta-CIT SPECT demonstrates reduced availability of serotonin transporters in patients with Fatal Familial Insomnia. J Neural Transm (Vienna). 2002 Jul;109(7-8):1105-10. doi: 10.1007/s007020200093. PMID: 12111447.
Cortelli P, Perani D, Montagna P, Gallassi R, Tinuper P, Provini F, Avoni P, Ferrillo F, Anchisi D, Moresco RM, Fazio F, Parchi P, Baruzzi A, Lugaresi E, Gambetti P. Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain. 2006 Mar;129(Pt 3):668-75. doi: 10.1093/brain/awl003. Epub 2006 Jan 6. Erratum in: Brain. 2008 Apr;131(4):1161. Federica, Provini [corrected to Provini, Federica]. PMID: 16399807.
Cramm M, Schmitz M, Karch A, Mitrova E, Kuhn F, Schroeder B, Raeber A, Varges D, Kim YS, Satoh K, Collins S, Zerr I. Stability and Reproducibility Underscore Utility of RT-QuIC for Diagnosis of Creutzfeldt-Jakob Disease. Mol Neurobiol. 2016 Apr;53(3):1896-1904. doi: 10.1007/s12035-015-9133-2. Epub 2015 Apr 1. PMID: 25823511; PMCID: PMC4789202.
Yang TW, Park B, Kim KT, Jun JS, Kim YS, Lee ST, Jung KH, Chu K, Lee SK, Jung KY. Fatal familial insomnia presenting with agrypnia excitata and very low atonia index level: A case report and literature review. Medicine (Baltimore). 2018 May;97(18):e0646. doi: 10.1097/MD.0000000000010646. PMID: 29718878; PMCID: PMC6392909.
C. W. Lindsley, “Genetic and Rare Disease of the CNS. Part I: Fatal Familial Insomnia (FFI).,” ACS chemical neuroscience, vol. 8, no. 12. United States, pp. 2570–2572, Dec. 2017, doi: 10.1021/acschemneuro.7b00463.
T. Fukuoka, Y. Nakazato, M. Yamamoto, A. Miyake, T. Mitsufuji, and T. Yamamoto, “Fatal Familial Insomnia Initially Developing Parkinsonism Mimicking Dementia with Lewy Bodies.,” Intern. Med., vol. 57, no. 18, pp. 2719–2722, Sep. 2018, doi: 10.2169/internalmedicine.0573-17.
L.-Y. Wu et al., “Expert Consensus on Clinical Diagnostic Criteria for Fatal Familial Insomnia.,” Chin. Med. J. (Engl)., vol. 131, no. 13, pp. 1613–1617, Jul. 2018, doi: 10.4103/0366-6999.235115
Burchell JT, Panegyres PK. Prion diseases: immunotargets and therapy. Immunotargets Ther. 2016 Jun 16;5:57-68. doi: 10.2147/ITT.S64795. PMID: 27529062; PMCID: PMC4970640.
Forloni G, Tettamanti M, Lucca U, Albanese Y, Quaglio E, Chiesa R, Erbetta A, Villani F, Redaelli V, Tagliavini F, Artuso V, Roiter I. Preventive study in subjects at risk of fatal familial insomnia: Innovative approach to rare diseases. Prion. 2015;9(2):75-9. doi: 10.1080/19336896.2015.1027857. PMID: 25996399; PMCID: PMC4601344.
Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B, Nanda A. Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurg Focus. 2015 Nov;39(5):E2. doi: 10.3171/2015.8.FOCUS15328. PMID: 26646926.
Krance SH, Luke R, Shenouda M, Israwi AR, Colpitts SJ, Darwish L, Strauss M, Watts JC. Cellular models for discovering prion disease therapeutics: Progress and challenges. J Neurochem. 2020 Apr;153(2):150-172. doi: 10.1111/jnc.14956. Epub 2020 Feb 3. PMID: 31943194.
Zhao MM, Feng LS, Hou S, Shen PP, Cui L, Feng JC. Gerstmann-Sträussler-Scheinker disease: A case report. World J Clin Cases. 2019 Feb 6;7(3):389-395. doi: 10.12998/wjcc.v7.i3.389. PMID: 30746381; PMCID: PMC6369391.
Mahat S, Asuncion RMD. Kuru. 2021 Jun 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32644529.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Barbara Madoń, Eryk Mikos, Justyna Nowaczek, Martyna Wasyluk, Natalia Wilczek

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 2559
Number of citations: 0